Free Trial

Apellis Pharmaceuticals (APLS) News Today

→ Jeff Bezos & 48 Members of Congress Are Buying ONE Sector… (From InvestorPlace) (Ad)
Free APLS Stock Alerts
$40.37
-0.68 (-1.66%)
(As of 06/7/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends
June 9 at 4:52 AM | marketbeat.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Sold by Bank of Nova Scotia
Bank of Nova Scotia lowered its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 97.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 6,443 shares of the company's stock after selling 286,862 shares during the perio
June 7 at 2:52 AM | americanbankingnews.com
Brokerages Set Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Target Price at $74.38
June 6 at 7:17 AM | marketbeat.com
Rafferty Asset Management LLC Decreases Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Rafferty Asset Management LLC decreased its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 33.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 143,118 shares of the company's stock after selling 71,043 shares
June 5, 2024 | globenewswire.com
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
June 4, 2024 | marketbeat.com
Rhenman & Partners Asset Management AB Lowers Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Rhenman & Partners Asset Management AB reduced its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 53.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned
June 4, 2024 | marketbeat.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Rating of "Moderate Buy" from Analysts
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) has earned an average recommendation of "Moderate Buy" from the sixteen brokerages that are covering the company, Marketbeat reports. Four analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation a
June 1, 2024 | marketbeat.com
Axiom Investors LLC DE Increases Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Axiom Investors LLC DE lifted its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 339.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,881 shares of the company's sto
June 1, 2024 | americanbankingnews.com
Apellis Pharmaceuticals (NASDAQ:APLS) Research Coverage Started at Piper Sandler
May 31, 2024 | marketbeat.com
Apellis Pharmaceuticals (NASDAQ:APLS) Trading Down 5.7%
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Down 5.7%
May 31, 2024 | marketbeat.com
Apellis Pharmaceuticals (NASDAQ:APLS) Coverage Initiated by Analysts at Piper Sandler
Piper Sandler started coverage on shares of Apellis Pharmaceuticals in a research note on Friday. They set a "neutral" rating and a $46.00 price objective for the company.
May 30, 2024 | marketbeat.com
Fiduciary Trust Co Sells 22,600 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Fiduciary Trust Co cut its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 8.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 242,607 shares of the company's stock after se
May 30, 2024 | americanbankingnews.com
Zacks Research Equities Analysts Increase Earnings Estimates for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
May 29, 2024 | marketbeat.com
Franklin Resources Inc. Purchases Shares of 229,790 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Franklin Resources Inc. purchased a new stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 229,790 shares of the company's stock, valued at approxim
May 29, 2024 | marketbeat.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) to Post Q4 2025 Earnings of $0.42 Per Share, Zacks Research Forecasts
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Stock analysts at Zacks Research reduced their Q4 2025 EPS estimates for shares of Apellis Pharmaceuticals in a research note issued on Monday, May 27th. Zacks Research analyst R. Department now expects that the company will earn $0.42 p
May 28, 2024 | finance.yahoo.com
The Future of Cannabidiol (CBD) Pain Treatments, 2024: Commercial and Clinical Assessment with Analysis of Pipeline Development Activities
May 28, 2024 | markets.businessinsider.com
Analysts Are Bullish on These Healthcare Stocks: Apellis Pharmaceuticals (APLS), Tango Therapeutics (TNGX)
May 28, 2024 | markets.businessinsider.com
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 Analysts
May 28, 2024 | marketbeat.com
Norges Bank Buys New Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Norges Bank bought a new stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 946,213 shares of the company's stock, valued at approximately $56,640,000. Norges
May 24, 2024 | globenewswire.com
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
May 23, 2024 | marketbeat.com
Apellis Pharmaceuticals (NASDAQ:APLS) Trading Down 5.9% After Analyst Downgrade
Apellis Pharmaceuticals (NASDAQ:APLS) Trading Down 5.9% After Analyst Downgrade
May 23, 2024 | marketbeat.com
Apellis Pharmaceuticals (NASDAQ:APLS) PT Lowered to $48.00 at Wells Fargo & Company
Wells Fargo & Company cut their target price on shares of Apellis Pharmaceuticals from $57.00 to $48.00 and set an "equal weight" rating on the stock in a research note on Thursday.
May 18, 2024 | marketbeat.com
Great Lakes Advisors LLC Invests $12.46 Million in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Great Lakes Advisors LLC purchased a new stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 208,163 shares of the company's stock, valued at approximately $12,461,000. Great Lakes Advis
May 17, 2024 | marketbeat.com
Apellis Pharmaceuticals, Inc. Forecasted to Earn Q2 2024 Earnings of ($0.41) Per Share (NASDAQ:APLS)
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Research analysts at Wedbush upped their Q2 2024 earnings per share (EPS) estimates for Apellis Pharmaceuticals in a report issued on Wednesday, May 15th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($
May 17, 2024 | marketbeat.com
BNP Paribas Financial Markets Sells 68,867 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
BNP Paribas Financial Markets decreased its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 29.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 167,488 shares of the company's stock after selling 68,867 shares durin
May 16, 2024 | marketbeat.com
Investors Buy High Volume of Call Options on Apellis Pharmaceuticals (NASDAQ:APLS)
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) saw some unusual options trading on Thursday. Investors purchased 40,472 call options on the company. This is an increase of 1,641% compared to the typical daily volume of 2,325 call options.
May 16, 2024 | marketbeat.com
Wedbush Comments on Apellis Pharmaceuticals, Inc.'s Q2 2025 Earnings (NASDAQ:APLS)
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Equities research analysts at Wedbush issued their Q2 2025 earnings per share estimates for shares of Apellis Pharmaceuticals in a research note issued to investors on Wednesday, May 15th. Wedbush analyst L. Chico expects that the compan
May 14, 2024 | marketbeat.com
Apellis Pharmaceuticals (NASDAQ:APLS) Trading Down 4%
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Down 4%
May 14, 2024 | marketbeat.com
Short Interest in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Expands By 16.1%
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) was the recipient of a large increase in short interest in April. As of April 30th, there was short interest totalling 12,390,000 shares, an increase of 16.1% from the April 15th total of 10,670,000 shares. Based on an average trading volume of 1,470,000 shares, the days-to-cover ratio is presently 8.4 days.
May 14, 2024 | finance.yahoo.com
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
May 13, 2024 | seekingalpha.com
Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks
May 11, 2024 | insidertrades.com
Pascal Deschatelets Sells 78,907 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock
May 10, 2024 | markets.businessinsider.com
Strong Performance and Growth Potential Affirm Buy Rating for Apellis Pharmaceuticals
May 10, 2024 | marketbeat.com
HC Wainwright Weighs in on Apellis Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:APLS)
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Equities researchers at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for shares of Apellis Pharmaceuticals in a note issued to investors on Wednesday, May 8th. HC Wainwright analyst D. Tsao now expects that the c
May 9, 2024 | marketbeat.com
Wedbush Analysts Reduce Earnings Estimates for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Investment analysts at Wedbush lowered their FY2026 earnings per share estimates for shares of Apellis Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 7th. Wedbush analyst L. Chico now expects that th
May 8, 2024 | markets.businessinsider.com
Apellis Pharmaceuticals Holds Steady Amid Market Challenges and Competitive Pressures
May 8, 2024 | msn.com
Apellis stock sell-off over Syfovre sales "overdone," says Citi
May 8, 2024 | markets.businessinsider.com
In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals
May 8, 2024 | marketbeat.com
Apellis Pharmaceuticals (NASDAQ:APLS) Given New $60.00 Price Target at Citigroup
Citigroup dropped their price target on Apellis Pharmaceuticals from $67.00 to $60.00 and set a "buy" rating on the stock in a research report on Wednesday.
May 8, 2024 | marketbeat.com
Apellis Pharmaceuticals' (APLS) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright restated a "buy" rating and set a $92.00 price objective on shares of Apellis Pharmaceuticals in a research report on Wednesday.
May 8, 2024 | marketbeat.com
Apellis Pharmaceuticals (NASDAQ:APLS) Issues Quarterly Earnings Results, Meets Estimates
Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.54) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.54). The company had revenue of $172.33 million for the quarter, compared to analyst estimates of $163.37 million. Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The business's revenue for the quarter was up 284.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.56) EPS.
May 8, 2024 | finance.yahoo.com
Apellis Pharmaceuticals First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
May 7, 2024 | finanznachrichten.de
Apellis Pharmaceuticals, Inc.: Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
May 7, 2024 | msn.com
APLS Stock Earnings: Apellis Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024
May 7, 2024 | seekingalpha.com
Apellis Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation
May 7, 2024 | marketbeat.com
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Down to $48.81
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Down to $48.81
May 7, 2024 | msn.com
Apellis Pharmaceuticals GAAP EPS of -$0.54 misses by $0.09, revenue of $172.3M beats by $8.04M
May 7, 2024 | globenewswire.com
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
May 7, 2024 | marketbeat.com
Victory Capital Management Inc. Has $36.89 Million Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Victory Capital Management Inc. lessened its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 16.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 616,272 shares of the
May 6, 2024 | marketbeat.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Holdings Decreased by Lisanti Capital Growth LLC
Lisanti Capital Growth LLC trimmed its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 58.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 46,305 shares of the company's stock after selling 64,695
May 6, 2024 | globenewswire.com
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
Get Apellis Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.

Biden Nomination CANCELED? (Ad)

And I believe when they do take the oath of office, their fingers will be crossed… and America will descend into chaos.

Click here now to see my urgent election warning.

APLS Media Mentions By Week

APLS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

APLS
News Sentiment
▼
0.70

0.76
▲
Average
Medical
News Sentiment

APLS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

APLS Articles
This Week
▼
6

8
▲
APLS Articles
Average Week

Get Apellis Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:APLS) was last updated on 6/9/2024 by MarketBeat.com Staff

From Our Partners
Collapse of the Petrodollar
The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...
Colonial Metals | Sponsored
Top 5 Tech Stocks to Buy for 2024
The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...
Daily Market Alerts | Sponsored
Top 5 AI Stocks to Buy for 2024
The electric vehicle boom is accelerating – and fast.
Market Moving Trends | Sponsored
No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free
Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...
Hedgeye | Sponsored
The Only Energy Play You Should Be Looking At
Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...
Wealthpin Pro | Sponsored
Bill Clinton Backing Biden Replacement???
Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...
The Freeport Society | Sponsored
Exposed: 3 CENT Crypto to Explode June 24th?
Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...
True Market Insiders | Sponsored
RSVP: Charles Payne’s Cash Flow Workshop
Did you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...
Unstoppable Prosperity | Sponsored